According to the Complaint, Correvio Pharma Corp. is a specialty pharmaceutical company that engages in developing therapeutics worldwide. The Company's portfolio of marketed brands comprise, among others,
vernakalant IV, or Brinavess, for the rapid conversion of recent onset AF to sinus rhythm.
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.